간전이 치료 시장 : 약제 클래스별, 원발 암, 유통 채널, 세계 예측(2024-2032년)

Global Liver Metastases Treatment Market will register over 6.7% CAGR from 2024 to 2032, driven by the rising incidence of primary cancers, such as colorectal and breast cancer, which commonly metastasize to the liver. According to the American Cancer Society, approximately 149,500 new cases of colorectal cancer and 297,790 new cases of breast cancer were diagnosed in the United States in 2023. Advancements in medical technology and oncology research have led to the development of innovative treatment modalities, including targeted therapies, immunotherapies, and minimally invasive surgical techniques, which offer improved patient outcomes and reduced side effects.

Additionally, increasing healthcare expenditure, growing awareness about the importance of early diagnosis and treatment, and the expanding availability of specialized healthcare services are further propelling market growth. Pharmaceutical companies are investing heavily in R&D to introduce novel therapies, while favorable regulatory policies are accelerating the approval process for new treatments. These factors combinedly shape the market dynamics.

The liver metastases treatment market is sorted based on drug class, primary cancer, distribution channel, and region.

The chemotherapy segment will experience a remarkable CAGR through 2032, because of efficacy in targeting liver metastases, linked with advancements in drug formulations and delivery mechanisms. Chemotherapy drugs have shown significant improvements in controlling tumor growth and extending patient survival rates. The development of more personalized & targeted chemotherapy options has enhanced treatment outcomes and reduced side effects, making these drugs a preferred choice in managing liver metastases.

The breast cancer segment will clutch a notable liver metastases treatment market share by 2032, owing to the increasing incidence of metastatic progression in breast cancer patients. As survival rates improve with early detection and treatment, a higher number of patients are living long enough for their cancer to metastasize to the liver. This highlights a greater need for effective treatments targeting liver metastases. Additionally, advancements in personalized medicine and targeted therapies have further enhanced treatment efficacy for breast cancer led liver metastases.

Europe liver metastases treatment industry will record a promising CAGR during the forecast period, because of the aging population and increased cancer incidence rates. Enhanced healthcare infrastructure and access to advanced medical technologies have improved diagnostic capabilities, leading to earlier detection and more effective treatment options. The healthcare policies of the region focus on personalized treatment approaches, spurring the adoption of innovative therapies. Increased funding for cancer R&D contributes to the availability of new and improved treatment modalities, thus augmenting the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of cancer
    • 3.2.1.2 Advancements in treatment modalities
    • 3.2.1.3 Increasing awareness and screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with medications
    • 3.2.2.2 Stringent regulatory scenarios
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Targeted therapy drugs
• 5.3 Chemotherapy drugs
• 5.4 Immunotherapy drugs

Chapter 6 Market Estimates and Forecast, By Primary Cancer, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Colorectal cancer
• 6.3 Breast cancer
• 6.4 Lung cancer
• 6.5 Other cancers

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Specialty pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca
• 9.2 Bayer AG
• 9.3 Bristol-Myers Squibb Company
• 9.4 Cadila Pharmaceuticals Ltd.
• 9.5 Eli Lilly and Company
• 9.6 F. Hoffmann-La Roche Ltd.
• 9.7 Merck & Co. Inc.
• 9.8 Novartis AG
• 9.9 Ono Pharmaceutical
• 9.10 Pfizer, Inc.